Clinical Trial Update: Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial is planned to compare Otezla (apremilast) and the investigational SFA-002 to placebo for plaque psoriasis, with the study currently not yet re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• OTEZLA (apremilast)
• SFA-002

Snippet

Sponsor: SFA Therapeutics | Conditions: Psoriasis (PsO) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING